Communiqués Lunit Inc.

Actions

A328130

KR7328130000

Equipement et technologie médicale avancés

Cours en clôture Korea S.E. 02/10/2026			Varia. 5j.	Varia. 1 janv.
10 570,00 ^KRW	-4,77%		-9,43%	-48,56%

28/09	Lunit étend Lunit Insight MMG en tant que second lecteur indépendant à l’ensemble de la région de Stockholm, en Suède	CI
10/09	Lunit annonce une collaboration avec 10x Genomics pour intégrer l'analyse pathologique par IA aux données moléculaires spatiales dans la recherche clinique en oncologie	CI

Communiqués

01/10	XAID Ranks Top 7 AI Radiology Platforms for Teleradiology Groups	AQ
16/07	CellCarta Launches Digital Pathology and AI Consortium to Accelerate Platform-Agnostic Biomarker Innovation Across Drug Development	AQ
11/06	Karolinska Institutet: AI is not just another technology. Medicinsk Vetenskap has spoken to researchers who describe their hopes and fears amid the current AI fever.	AQ
26/11/24	Lunit to Showcase Research Contributions at RSNA 2024 with Record-Breaking 20 Abstracts	AQ
11/11/24	Lunit Shows Promise of AI in Predicting Immunotherapy Response for Rare Cancer Patients at SITC 2024	AQ
24/10/24	Lunit AI Predicts Breast Cancer Risk Up to 6 Years in Advance	AQ
23/07/24	Lunit's AI Solution Enhances Qatar's National Breast Cancer Screening Program	AQ
27/03/24	Lunit SCOPE IO Reveals Promising Results in Neoadjuvant Immunotherapy Study for Head and Neck Cancer Patients	AQ
15/03/24	Lunit SCOPE AI Enhances Pathologist Concordance and Accuracy in HER2, ER, and PR Assessment, New Study in Breast Cancer Research	AQ
29/02/24	Lunit Presents Seven Study Results at ECR 2024, Showcasing AI's Robust Performance in Diverse Clinical Settings	AQ
19/02/24	New Study Demonstrates Predictive Value of Lunit SCOPE IO to Predict Outcomes of Immune Checkpoint Inhibitor Therapy across Diverse Tumors, published in the JITC	AQ
18/01/24	Lunit INSIGHT CXR Excels in Long Nodule Detection, Exceptional Performance in Head-to-Head Study published in Radiology	AQ
12/12/23	Lunit Advances to Stage 2 of Australia s National Breast Cancer Screening Project	AQ
16/11/23	Lunit Secures $150 Million in Capital Increase	AQ
15/11/23	Lunit Nets FDA Nod for AI-Powered 3D Breast Tomosynthesis Solution, Lunit INSIGHT DBT	AQ
27/10/23	Lunit Participates in Saudi Vision 2030 Healthcare Sandbox, Accelerating Saudi Arabia's Healthcare Transformation	AQ
25/10/23	First Immunotherapy Success in TKI-Resistant Lung Cancer Setting Demonstrates Power of AI-driven Immune Phenotyping by Lunit SCOPE IO, newly published in JCO	AQ
17/10/23	New Study Demonstrates Lunit SCOPE IO's Effectiveness to Predict Biliary Tract Cancer Therapy Outcomes, Findings to be presented at the ESMO 2023	AQ
22/08/23	Lunit Backs the Potential of Tertiary Lymphoid Structures Analysis as an Emerging Biomarker for Lung Cancer Treatment to be presented at WCLC 2023	AQ
31/05/23	Lunit and the Japan National Cancer Center Hospital East Partner in AI Pathology to Advance Precision Oncology	AQ
12/08/22	Top Artificial Intelligence Trends Influencing the Future of Radiology	AQ
22/07/22	NVIDIA -Shifting Into High Gear: Lunit, Maker of FDA-Cleared AI for Cancer Analysis, Goes Public in Seoul	AQ